DALLAS, Oct. 2, 2009 (GLOBE NEWSWIRE) -- BeaconEquity.com announces an investment report featuring Talecris Biotherapeutics Holding Corp. (Nasdaq:TLCR). The report includes financial, comparative and investment analyses, and pertinent industry information you need to know to make an educated investment decision.
The investment report on Talecris Biotherapeutics Holding Corp. (Nasdaq:TLCR) should be of particular interest to biopharmaceutical companies: Novartis AG (NYSE:NVS), AstraZeneca plc (NYSE:AZN), Bristol-Myers Squibb Co. (NYSE:MRK) and Human Genome Sciences (Nasdaq:HGSI).
It is available at: http://www.beaconequity.com/i/TLCR
Get our alerts BEFORE the rest of the market. Follow us on Twitter: http://twitter.com/BeaconEquity
Talecris Biotherapeutics Holding Corp. (TLCR) is a biopharmaceutical company that produces and markets plasma-derived protein therapies worldwide. The Company develops, produces, markets and distributes therapies that help people suffering from conditions, such as immune deficiency disorders, alpha-1 antitrypsin (AAT) deficiency, infectious diseases, hemophilia and severe burns.
In the report, the analyst notes:
"TLCR yesterday announced that the pricing of its initial public offering (IPO) of 50 million shares of its common stock at a price of $19 per share. Of the shares being offered, 28,947,368 are being offered by the Company and 21,052,632 are being offered by the selling stockholder, Talecris Holdings LLC. Talecris Holdings LLC is owned by Cerberus Plasma Holdings LLC, the managing member of which is Cerberus Partners L.P., and limited partnerships affiliated with Ampersand Ventures. The underwriters have the option to purchase from the selling stockholder up to an additional 6 million shares of common stock.
"TLCR recently presented results from two phase III studies assessing the safety, tolerability and pharmacokinetic comparability of a more concentrated formulation of Prolastin(R) (Alpha1-Proteinase Inhibitor [Human]) produced though a modification of the current manufacturing process that incorporates technological changes."
To read the entire report visit: http://www.beaconequity.com/i/TLCR
See what investors are saying about these stocks at: http://www.stockhideout.com/
BeaconEquity.com is one of the industry's largest small-cap report providers. Beacon strives to provide a balanced view of many promising small-cap companies that would otherwise fall under the radar of the typical Wall Street investor. We provide investors with an excellent first step in their research and due diligence by providing daily trading ideas, and consolidating the public information available on them. For more information on Beacon Research, please visit http://www.BeaconEquity.com
Beacon Equity Disclosure
DO NOT BASE ANY INVESTMENT DECISION UPON ANY MATERIALS FOUND ON THIS REPORT. We are not registered as a securities broker-dealer or an investment adviser either with the U.S. Securities and Exchange Commission (the "SEC") or with any state securities regulatory authority. We are neither licensed nor qualified to provide investment advice. BeaconEquity Research nor its affiliates have a beneficial interest in the mentioned company; nor have they received compensation of any kind for any of the companies listed in this communication. The information contained in our report is not an offer to buy or sell securities. We distribute opinions, comments and information free of charge exclusively to individuals who wish to receive them.